Can Depo-Provera (medroxyprogesterone acetate) cause anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Depo-Provera Cause Anxiety?

Depo-Provera (DMPA) is not associated with causing anxiety based on available evidence, though it has been studied for its effects on depression with reassuring findings. The major documented adverse effects include menstrual irregularities, weight gain, headache, mastalgia, hair loss, and changes in libido—but anxiety is not listed among recognized side effects in clinical guidelines 1.

Evidence on Mood Effects

The relationship between DMPA and mood disorders has been specifically investigated, with findings that are generally reassuring:

Depression Studies (Most Relevant to Mood)

  • A prospective study of adolescents using DMPA found that depressive symptoms actually improved over 12 months of use, with mean Beck Depression Inventory scores decreasing by 4.8 points (p=0.02), and no significant changes in negative or positive affect were observed 2.

  • Among adult DMPA users followed for one year, women who continued the method had lower baseline depressive symptom scores, and those scores improved slightly at follow-up (7.4 vs 6.7), with subjects having the highest depression scores at enrollment showing improvement over time 3.

  • A cross-sectional study of DMPA users found no evidence of increasing depression with long-term use and no short-term dose-related effects on mood, leading researchers to conclude that women at risk of depression should not be denied DMPA as a contraceptive choice 4.

Important Exception - Immediate Postnatal Use

  • One randomized controlled trial found that DMPA administered within 48 hours of childbirth was associated with higher depression scores at 1 and 3 months postpartum compared to IUD users (p=0.04 at 1 month, p=0.002 at 3 months), though this specific context (immediate postnatal period) represents a unique hormonal environment 5.

Clinical Guideline Perspective

Major clinical guidelines from the American College of Pediatrics and CDC list the recognized adverse effects of DMPA as menstrual irregularities, headache, mastalgia, hair loss, change in libido, and weight gain—but do not include anxiety or mood disorders as documented side effects 1.

Clinical Recommendations

  • If a patient reports anxiety while using DMPA, evaluate for other causes of anxiety rather than automatically attributing it to the contraceptive, as the evidence does not support a causal relationship 1, 3, 4, 2.

  • Counsel patients that mood-related concerns should not preclude DMPA use, as prospective studies show either no effect or improvement in depressive symptoms over time 3, 4, 2.

  • Consider alternative contraceptive methods if anxiety symptoms are severe and temporally related to DMPA initiation, using shared decision-making to optimize both contraceptive efficacy and quality of life 1.

Common Pitfalls to Avoid

  • Do not dismiss patient-reported anxiety symptoms, even though they are not documented side effects—evaluate comprehensively for other medical and psychosocial causes 1.

  • Avoid withholding DMPA from patients with pre-existing anxiety disorders based solely on theoretical concerns, as the evidence does not support worsening of mood symptoms with use 4.

  • Do not confuse the immediate postnatal context (where some depression risk may exist) with routine DMPA use in non-postpartum patients, as these represent different clinical scenarios 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Depressive symptoms and Depo-Provera.

Contraception, 1998

Research

The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial.

The journal of family planning and reproductive health care, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.